A large French study has shown that the vast
majority of people living with HIV who started treatment since 2000 in a
national cohort achieved a CD4 cell count in the normal range within three to
four years of starting treatment, while a large Italian study showed that
achieving a normal CD4 count on

An oral regimen of
sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C
patients with decompensated cirrhosis, the most advanced stage of liver
disease, according to a presentation on Tuesday at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting in Boston.
Over years or decades,
chronic hepatitis C virus (HCV)

People with HIV – most of whom had hepatitis B
or C co-infection – generally had good outcomes after liver transplantation due
to hepatocellular carcinoma (HCC), with five-year survival rates similar to
those of HIV-negative transplant recipients and better than those of people who
underwent other types of liver cancer treatment, researchers reported this

One of the key strategies involved in trying to bring an end
to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral
therapy (ART), to the point where suppressing their viral load starts to reduce
onward infection.
What is usually called ‘treatment as prevention’ lies behind
the
ambitious new target announced

Young people who inject drugs (PWID) who undergo opioid
agonist maintenance therapy with methadone or buprenorphine have more than a
60% reduced risk of acquiring hepatitis C virus (HCV) over time
compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study
of Liver

There was widespread misunderstanding and misinterpretation of questions
about anal sex being asked of participants inthe Vaginal
and Oral Interventions to Control the Epidemic (VOICE) trial existed, according to findings of a qualitative
ancillary study to the VOICE trial qualitative
analysis study (called MTN-003D or VOICE-D) presented at the HIV Research for Prevention conference

Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.

Dolutegravir is also a component of

Treatment with a triple
antiretroviral combination containing once-daily integrase inhibitor dolutegravir
(Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir
(Prezista) over 96 weeks of follow up,Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the Internatinal Congress of
Drug Therapy in HIV Infection in Glasgow last week.

Dolutegravir is also a component of

People who achieve
sustained virological response (SVR) when treated with interferon-based therapy
for hepatitis C have a lower risk of death, are less likely to develop liver
cancer and need fewer liver transplants than those who were treated but not cured,
according to results from a meta-analysis of more than 34,000 patients
presented Sunday at

All but one
participant treated with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological
response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat
HIV/HCV coinfected patients, researchers reported Sunday at the American Association for the Study
of Liver Diseases (AASLD) Liver Meeting in Boston.
Sofosbuvir/ledipasvir –
a combination nucleotide HCV polymerase